Unravelling data for rapid evidence-based response to COVID-19: a summary of the unCoVer protocol

Author:

Peñalvo José L.ORCID,Mertens EllyORCID,Ademović Enisa,Akgun Seval,Baltazar Ana Lúcia,Buonfrate DoraORCID,Čoklo Miran,Devleesschauwer Brecht,Diaz Valencia Paula Andrea,Fernandes João C.,Gómez Enrique Javier,Hynds Paul,Kabir Zubair,Klein JörnORCID,Kostoulas Polychronis,Llanos Jiménez Lucía,Lotrean Lucia Maria,Majdan Marek,Menasalvas Ernestina,Nguewa Paul,Oh In-Hwan,O’Sullivan Georgie,Pereira David M.,Reina Ortiz MiguelORCID,Riva Silvia,Soriano Gloria,Soriano Joan B.,Spilki Fernando,Tamang Mary Elizabeth,Trofor Antigona Carmen,Vaillant MichelORCID,Van Ierssel Sabrina,Vuković Jakov,Castellano José M.

Abstract

IntroductionunCoVer—Unravelling data for rapid evidence-based response to COVID-19—is a Horizon 2020-funded network of 29 partners from 18 countries capable of collecting and using real-world data (RWD) derived from the response and provision of care to patients with COVID-19 by health systems across Europe and elsewhere. unCoVer aims to exploit the full potential of this information to rapidly address clinical and epidemiological research questions arising from the evolving pandemic.Methods and analysisFrom the onset of the COVID-19 pandemic, partners are gathering RWD from electronic health records currently including information from over 22 000 hospitalised patients with COVID-19, and national surveillance and screening data, and registries with over 1 900 000 COVID-19 cases across Europe, with continuous updates. These heterogeneous datasets will be described, harmonised and integrated into a multi-user data repository operated through Opal-DataSHIELD, an interoperable open-source server application. Federated data analyses, without sharing or disclosing any individual-level data, will be performed with the objective to reveal patients’ baseline characteristics, biomarkers, determinants of COVID-19 prognosis, safety and effectiveness of treatments, and potential strategies against COVID-19, as well as epidemiological patterns. These analyses will complement evidence from efficacy/safety clinical trials, where vulnerable, more complex/heterogeneous populations and those most at risk of severe COVID-19 are often excluded.Ethics and disseminationAfter strict ethical considerations, databases will be available through a federated data analysis platform that allows processing of available COVID-19 RWD without disclosing identification information to analysts and limiting output to data aggregates. Dissemination of unCoVer’s activities will be related to the access and use of dissimilar RWD, as well as the results generated by the pooled analyses. Dissemination will include training and educational activities, scientific publications and conference communications.

Funder

Horizon 2020 Framework Programme

Publisher

BMJ

Subject

General Medicine

Reference10 articles.

1. World Health Organization . Expanding our understanding of post COVID-19 condition: report of a who webinar, 2021 [Accessed 09 Feb 2021].

2. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

3. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan

4. World Health Organization (WHO) . COVID-19 clinical management: living guidance, 2021. Available: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1

5. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches;Jin;Signal Transduct Target Ther,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3